Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Core Points - Onconetix, Inc. received a notification from Nasdaq regarding its failure to file the Quarterly Report on Form 10-Q for the period ended September 30, 2024, which is a violation of Nasdaq's continued listing requirements [1] - The Company subsequently filed the Form 10-Q with the Securities and Exchange Commission on December 10, 2024, in compliance with Nasdaq Listing Rule 5810(b) [2] - Onconetix is a biotechnology company focused on men's health and oncology, owning Proclarix®, an in vitro diagnostic test for prostate cancer, and ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia [3]